<DOC>
	<DOCNO>NCT00323375</DOCNO>
	<brief_summary>The purpose protocol perform Phase 1 ( safety/toxicity pharmacokinetic ) Studies investigational aminoquinoline antimalarial ( AQ-13 ) human subject . The compound study ( AQ-13 ) examine active vitro Plasmodium falciparum malaria parasites resistant chloroquine ( CQ ) antimalarial ( multi-resistant P. falciparum ) , safety similar CQ preclinical study perform SRI International ( IND 55,670 ) . AQ-13 also select study active vivo two monkey model human malaria : 1 ] P. cynomolgi rhesus monkey ( Macaca mulatta ) , model human infection P. vivax , 2 ] CQ-resistant P. falciparum squirrel monkey , model human infection CQ-resistant P. falciparum .</brief_summary>
	<brief_title>Phase 1 Studies AQ-13 , Candidate Aminoquinoline Antimalarial , Comparison With Chloroquine</brief_title>
	<detailed_description>Study Population : Healthy young men woman 21-45 year age take chronic medication exception birth control pill invite participate Phase 1 Study Tulane/LSU/Charity Hospital General Clinical Research Center ( GCRC ) New Orleans . Exclusion criterion include pregnancy , breast feeding , abnormal liver kidney function test , anemia ( Hb &lt; 12 gm per dL ) , chronic medication birth control pill , abnormal baseline ECG Holter recording . Because purpose test determine whether AQ-13 likely significant toxicity Africans ( Malians ) , ≥ 25 % volunteer study New Orleans African-Americans . Randomization : Drug allocation code generate study biostatistician block size 4 6 , use computer software , seal number , opaque envelops . Block size determine random know study personnel . The envelope contain randomization code hand-delivered study pharmacist keep Research Pharmacy , outside GCRC . Blinding : The study participant , investigator staff blind type drug administer throughout study . The interim report DSMB completion dose level present without break code , unless deem necessary DSMB . The envelope contain drug allocation code open study pharmacist appropriate drug dispense GCRC morning administration . With exception 600 mg CQ tablet ( Aralen™ ) tablet , two drug ( AQ-13 CQ ) administer identical capsular form number . Informed Consent : Informed consent obtain participant screening . As per IRB regulation , informed consent form update review yearly interval whenever new pertinent information study drug side effect become available . Baseline Screening : To determine eligibility , volunteer complete physical exam , include eye examination ( visual acuity , visual field , indirect ophthalmoscopy ) , panels standard chemical test ( BUN , Creatinine , AST , ALT , LDH , Alkaline Phosphatase , Glucose , Bilirubin , Creatine Kinase ) hematologic test ( Hematocrit , Hemoglobin , White Cell Count Platelet Count ) , cardiac examination ( physical exam , baseline ECG 24-hour Holter record ) arrhythmia evidence cardiac disease . In-patient Studies Tulane-LSU-Charity Hospital GCRC : Volunteers hospitalize night drug administration GCRC , prior randomization receive either AQ-13 CQ capsule orally ( po ) next morning . Doses begin 10 mg base 8 volunteer per drug x dose group , escalate subsequent group 100 , 300 600 mg base ( 8 subject per drug x dose group 10 , 100 300 mg dos [ subtotal 48 subject ] ; 12 subject per drug x dose group 600 mg dose order compare pharmacokinetics CQ AQ-13 proceed equivalent therapeutic dose ) . At request FDA , third group add 600 mg dose determine whether blood level obtain CQ capsule equivalent blood level obtain commercially available FDA-approved Sanofi-Winthrop CQ tablet ( Aralen™ , i.e. , 12 subject per drug x dose group 600 mg x 3 drug group [ AQ-13 capsule , CQ capsule Aralen™ CQ tablet ] = subtotal 36 subject ] ) . To compare absorption metabolism AQ-13 absorption metabolism CQ , blood sample obtain AQ-13 , CQ metabolite blood level immediately 1 , 2 , 4 , 6 , 8 , 12 , 18 , 24 , 36 , 48 , 60 , 72 , 84 , 96 120 hour 600 1500 mg dos use heparin lock . At 1500 mg dose , three 24-hour urine collection obtain day 1-3 begin dose day 1 compare urinary excretion AQ-13 , CQ metabolites . Volunteers receive 600 1500 mg dose AQ-13 CQ return blood sample twice weekly ensue 4 week define terminal half-lives AQ-13 , CQ metabolites . After measurement AQ-13 , CQ metabolite level follow 600 mg dose , dos give second set study ( equivalent therapeutic course – i.e. , 1500 mg CQ ) adjust ( Dose Adjustment , see ) obtain blood level AQ-13 similar obtain CQ . In study , volunteer receive equivalent 600 mg CQ base morning day 1 2 , additional 300 mg CQ base equivalent day 3 . Previous experience CQ ( structurally similar aminoquinoline ) suggest massive overdoses AQ-13 may produce arrhythmia , although previous human experience AQ-13 . Although arrhythmiagenic effect CQ report massive ingestion rapid intravenous infusion , Phase 1 Studies provide excellent opportunity test potential toxicity . Therefore , use Holter monitoring Phase 1 Studies New Orleans ensure evidence arrhythmia AQ-13 . Conventional electrocardiogram use test T wave flatten QTc prolongation , typically see person receive therapeutic course CQ . Continuous Holter monitoring perform evaluate effect AQ-13 CQ QT interval 1500 mg dose . Participants ’ Out-patient Follow-ups : After discharge in-patient stay GCRC ( 2½ day 10 , 100 , 300 600 mg dos ; 3½ day 1500 mg dose ) , participant ask return GCRC twice weekly total 4 week discharge order obtain blood drug metabolite blood level , evaluation adverse event ( AEs ) . An ECG chemistry hematology lab test repeat 2 week 4 week follow-up visit . Dose Adjustment AQ-13 : The data obtain SRI International GLP preclinical toxicologic pharmacokinetic study indicate oral bioavailability AQ-13 le CQ rat monkey . Therefore , possible ( perhaps likely ) oral bioavailability AQ-13 human less CQ , thus may necessary increase oral dose AQ-13 order provide molar blood level AQ-13 similar produce established oral dos CQ . To estimate amount AQ-13 necessary obtain similar oral bioavailability , compare blood level area curve ( AUCs ) AQ-13 CQ 600 mg dose . Based result , estimate dose adjustment ( increment decrement ) necessary AQ-13 test adjustment 12 additional volunteer . After dose AQ-13 necessary produce equimolar blood level AUCs establish , compare adjust dose 1500 mg CQ base equivalent therapeutic dose AQ-13 .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Chloroquine</mesh_term>
	<mesh_term>Chloroquine diphosphate</mesh_term>
	<mesh_term>Antimalarials</mesh_term>
	<criteria>Healthy adult volunteer 21 45 year age Chronic medication exception oral contraceptive Pregnancy Breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2005</verification_date>
	<keyword>Malaria</keyword>
	<keyword>Aminoquinolines</keyword>
	<keyword>Drug Resistance</keyword>
	<keyword>Chloroquine Resistance</keyword>
</DOC>